Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

ASP3082 grabs some early attention among degraders set to feature at ESMO.

Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.

The FDA throws out the company’s second attempt at an accelerated approval.

While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.